AI Software for Endocrinology
Powered with Artificial Intelligence. Built for Human Intelligence.
AI Software for Endocrinology from Unlimited Systems predicts which injectables and devices will need approval and gathers the records payers ask for. It drafts codes from the visit note and flags claims likely to deny. Endocrine revenue rests on lab-driven decisions, payer frequency limits, and drugs that may fall under the medical or pharmacy benefit. Unlimited AI runs those checks in the background. Your team spends its time on patients and on the few accounts that need a decision.
The Practical Side of AI for Specialty Practices
Avoid the pitfalls, cut through the noise, and put AI to work on everyday challenges. With Johnathon Trout (JT), Director of Product Management.
AI Built Around the Realities of Endocrinology
An endocrinology clinic manages long-term disease and in-office services side by side. In one morning it may see diabetes follow-ups, a new thyroid nodule, an osteoporosis injection, and a CGM data review. Each one depends on labs, imaging, or device data stored in different places. Payers ask for bone density results, prior therapies, and test values before they approve treatment. AI earns its place by pulling those facts together and flagging only the orders and claims that fall short.
- Osteoporosis injectables such as denosumab and romosozumab often need approval tied to DXA results, fracture history, and prior therapy.
- Some endocrine drugs are covered under the medical benefit and others under pharmacy. Ordering under the wrong one stalls treatment.
- Bone density scans billed with code 77080 carry payer frequency limits. A scan repeated too soon may not be covered.
- Ultrasound-guided thyroid biopsy codes 10005 and 10006 include the imaging guidance. Billing the guidance on its own breaks the edit.
- CGM interpretation under code 95251 has its own data and frequency rules. Device starts are coded apart from the review.
- Newer diabetes and weight-management drugs are approved by indication and plan. Coverage often hinges on the diagnosis and prior treatment.
Where AI Can Improve Endocrinology Operations
- Problem
- An osteoporosis biologic request is denied because the packet lacked a recent DXA or fracture history. The next dose slips while staff rebuild the request.
- Automation + Intelligence
- AI prior authorization checks each injectable order against the payer's criteria. It gathers bone density results, fracture history, and prior therapies from the chart for the request. Approvals and renewal dates are tracked against the patient's dosing plan.
- Human Benefit
- Prior auth staff send complete packets instead of chasing missing reports.
- Business Benefit
- Injection visits stay covered by a valid approval, which protects a major revenue line for the clinic.
- Problem
- Some endocrine drugs are billed by the practice under the medical benefit, while others must go through a pharmacy. A drug bought for the office that the plan only covers at pharmacy becomes a loss.
- Automation + Intelligence
- Before an order is placed, the benefit channel is confirmed for the drug, the plan, and the indication. Orders that need the pharmacy route are flagged at the order, not at the denial.
- Human Benefit
- Clinical staff learn the right channel before they order, not after the claim returns.
- Business Benefit
- Fewer drugs bought for in-office use that the plan will never pay the practice for.
- Problem
- Thyroid biopsies are easy to code against the edits. Guidance gets billed on its own, or the lesion count on the claim does not match the note.
- Automation + Intelligence
- Unlimited AI reads the procedure note and drafts 10005 for the first lesion and 10006 for each added one. It checks the set against NCCI edits, including the guidance that is already part of the biopsy code. Each code links to the note text that supports it.
- Human Benefit
- Coders confirm a cited draft instead of counting lesions in the dictation.
- Business Benefit
- Fewer bundling denials on thyroid procedures and a cleaner audit trail.
- Problem
- DXA scans and CGM reviews are paid only as often as the payer allows. A repeat billed too soon is denied after the service is already done.
- Automation + Intelligence
- The date of the last covered DXA or CGM interpretation is checked against payer frequency rules when the service is booked and again before the claim is built. Services that fall outside the rule are held with the reason attached.
- Human Benefit
- Schedulers and billers see the frequency problem while there is still time to act.
- Business Benefit
- Fewer frequency denials on imaging and device data reviews.
- Problem
- In-office injectables can be paid below what the practice paid for the drug. Those shortfalls look like normal payments unless each line is compared.
- Automation + Intelligence
- As remittances post, each injectable line is compared with what that payer is expected to pay for it. Shortfalls and possible negative-margin drugs are flagged, and authorization denials go to the right queue with the drug details attached.
- Human Benefit
- Billing managers see drug payment problems as they arrive, not at a yearly cost review.
- Business Benefit
- Underpaid drug lines are appealed while they can still be recovered.
- Problem
- Payers measure diabetes control and osteoporosis treatment after a fracture. The practice often learns about its gaps from a payer report long after the visit.
- Automation + Intelligence
- Open care gaps, such as a missing A1c result or no treatment after a fragility fracture, are tracked from the same records billing uses. Gaps appear ahead of upcoming visits so they can be closed in the room.
- Human Benefit
- Clinicians see the gap before the patient arrives, not in a report later.
- Business Benefit
- Better standing in quality programs and value-based contracts.
The Evolution of Intelligence in Endocrinology
Eligibility, benefit channel checks, and claim status requests run on their own for every visit, injection, and in-office procedure.
Injectable orders missing DXA or prior therapy records, scans booked before the frequency limit, and biopsy codes that break an edit are flagged.
Denied injectable claims and approvals near renewal move ahead of routine visit and lab claims.
Each flagged item names the fix, such as the bone density report the payer wants, the pharmacy route, or the lesion count to confirm.
Emerging capability: renewal requests for stable injectable plans could be sent on their own when every required record is on file. The platform is built to support this, but it is not live yet.
Work by Exception for Endocrinology
A patient is booked for a denosumab injection. The payer's renewal rule asks for a bone density result newer than the one in the chart.
Unlimited AI flags only that appointment and tells the prior auth team which record is missing. The other injection visits that day have valid approvals and move forward with no manual review.
AI Gathers the Records. Your Endocrine Team Makes the Decisions.
Endocrinologists build care plans over years of labs, devices, and medication changes. Their staff should be teaching insulin starts and answering patient questions. They should not be digging for a bone density report to finish an approval packet. Automation takes the lookups and checks. Every unclear benefit, code, or appeal still goes to a person who knows the patient.
AI Across the Endocrinology Revenue Cycle
Why Unlimited Systems for Endocrinology
- Approval requests for osteoporosis biologics and hormone therapies are built from the DXA, lab, and therapy history already in the chart.
- Medical versus pharmacy benefit is confirmed before an injectable is ordered.
- DXA and CGM frequency rules are checked at booking and again at charge entry.
- Each AI-drafted procedure code points to its source sentence, and drafts below the confidence threshold go to a coder.
- Drug payments are compared with expected rates at posting, so margin problems surface early.
Frequently Asked Questions About AI for Endocrinology
AI software for endocrinology automates the checks behind injectables, imaging, and in-office procedures. Unlimited AI predicts which orders need approval and gathers the records payers ask for. It drafts codes from visit and procedure notes, checks frequency limits for DXA and CGM services, and flags claims likely to deny. Routine work moves on its own, and staff review only the exceptions.
AI prior authorization checks each osteoporosis injectable order against the payer's rules before the visit is booked. It pulls DXA results, fracture history, and prior therapies from the chart, since those are the records payers usually ask for. Approvals and renewal dates are then tracked against the dosing plan, and staff are alerted before an approval runs out.
The benefit channel depends on the drug, the plan, and sometimes the diagnosis. The platform checks the channel before the order is placed. Drugs the plan covers only through pharmacy are flagged so the practice does not buy them for in-office use. Drugs covered under the medical benefit move on to approval checks and buy-and-bill charge entry.
Unlimited AI reads the procedure note and drafts code 10005 for the first lesion and 10006 for each added lesion. The ultrasound guidance is part of those codes, so it is not billed again on its own. Each drafted code links to the text that supports it. When the note is unclear about how many lesions were sampled, the draft goes to a coder.
Frequency denials happen when a covered service is repeated sooner than the payer allows. The platform checks the date of the last covered bone density scan or CGM interpretation against each payer's rule. The check runs when the service is booked and again at charge entry. Services outside the rule are held with the reason attached, so staff can reschedule or explain the patient's cost.
Quality programs look at diabetes control and treatment after a fragility fracture, among other measures. The platform tracks open gaps from the same records billing uses. Patients with a missing A1c result or untreated osteoporosis after a fracture show up before their next visit. The care team can then close the gap in the room instead of learning about it from a payer report.
Coders and billers stay in charge of the decisions. AI drafts cited codes, runs benefit and frequency checks, and sorts denials by value and deadline. Coders review drafts and handle complex procedure notes. Billers work injectable appeals and payer calls that need judgment. Every automated change is logged, so the team can see what the system did and why.
GET STARTED
See What AI Can Do for Your Endocrinology Practice
AI Software for Endocrinology from Unlimited Systems predicts which injectables and devices will need approval and gathers the records payers ask for. It drafts codes from the visit note and flags claims likely to deny. Endocrine revenue rests on lab-driven decisions, payer frequency limits, and drugs that may fall under the medical or pharmacy benefit. Unlimited AI runs those checks in the background. Your team spends its time on patients and on the few accounts that need a decision.
6,500+ specialty providers